Compare Stocks: NLTX, SVRA, KURA, and MLTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$9.61 -2.2%	$11.39	$7.36 ▼ $13.90	$874.49M	0.47	1.80 million shs	1.83 million shs
MLTX MoonLake Immunotherapeutics	$10.14 -2.6%	$13.83	$8.80 ▼ $23.29	$885.96M	1.08	2.02 million shs	1.77 million shs
NLTX Neoleukin Therapeutics	$21.56 -11.8%	$33.67	$2.03 ▼ $14.36	$202.62M	1.11	50,104 shs	442,253 shs
SVRA Savara	$4.76 -0.4%	$5.28	$3.38 ▼ $7.01	$982.10M	0.2	2.49 million shs	2.57 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	-2.24%	-9.93%	-16.87%	-11.75%	-0.10%
MLTX MoonLake Immunotherapeutics	-2.59%	-5.85%	-20.03%	-46.66%	0.00%
NLTX Neoleukin Therapeutics	-11.78%	-15.28%	-39.23%	-45.35%	-31.82%
SVRA Savara	-0.42%	-2.46%	-10.86%	-13.77%	+40.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$9.61 -2.2%	$11.39	$7.36 ▼ $13.90	$874.49M	0.47	1.80 million shs	1.83 million shs
MLTX MoonLake Immunotherapeutics	$10.14 -2.6%	$13.83	$8.80 ▼ $23.29	$885.96M	1.08	2.02 million shs	1.77 million shs
NLTX Neoleukin Therapeutics	$21.56 -11.8%	$33.67	$2.03 ▼ $14.36	$202.62M	1.11	50,104 shs	442,253 shs
SVRA Savara	$4.76 -0.4%	$5.28	$3.38 ▼ $7.01	$982.10M	0.2	2.49 million shs	2.57 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	-2.24%	-9.93%	-16.87%	-11.75%	-0.10%
MLTX MoonLake Immunotherapeutics	-2.59%	-5.85%	-20.03%	-46.66%	0.00%
NLTX Neoleukin Therapeutics	-11.78%	-15.28%	-39.23%	-45.35%	-31.82%
SVRA Savara	-0.42%	-2.46%	-10.86%	-13.77%	+40.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KURA Kura Oncology	2.77	Moderate Buy	$25.35	163.82% Upside
MLTX MoonLake Immunotherapeutics	2.43	Hold	$28.50	181.07% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
SVRA Savara	2.75	Moderate Buy	$10.25	115.34% Upside

Current Analyst Ratings Breakdown

Latest NLTX, SVRA, KURA, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/14/2026	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$24.00
10/14/2026	KURA Kura Oncology	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$24.00
10/14/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/7/2026	SVRA Savara	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$10.00
10/7/2026	SVRA Savara	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/7/2026	SVRA Savara	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00
10/5/2026	KURA Kura Oncology	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$50.00
10/1/2026	KURA Kura Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$30.00
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KURA Kura Oncology	$77.23M	11.07	N/A	N/A	$2.00 per share	4.81
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	N/A	N/A	N/A	-37.22%	-30.91%	N/A
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest NLTX, SVRA, KURA, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	SVRA Savara	-$0.1633	N/A	N/A	N/A	$0.50 million	N/A
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	KURA Kura Oncology	-$0.8144	N/A	N/A	N/A	$23.81 million	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KURA Kura Oncology	0.12	4.73	4.71
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KURA Kura Oncology	N/A
MLTX MoonLake Immunotherapeutics	93.85%
NLTX Neoleukin Therapeutics	52.37%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
KURA Kura Oncology	7.60%
MLTX MoonLake Immunotherapeutics	10.40%
NLTX Neoleukin Therapeutics	1.58%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
SVRA Savara	70	205.46 million	194.57 million	Optionable

NLTX, SVRA, KURA, and MLTX Headlines

Recent News About These Companies

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

October 13 at 12:08 PM | finance.yahoo.com

Savara Inc. (SVRA) - What Are Analysts Thinking About This Stock?

October 13 at 4:15 AM | americanbankingnews.com

Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts

October 13 at 4:13 AM | marketbeat.com

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis ...

October 12 at 8:40 PM | joplinglobe.comJ

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

October 12 at 4:05 PM | businesswire.com

JPMorgan starts Savara coverage with USD 12 target for Savara stock

October 8, 2026 | ad-hoc-news.deA

Savara stock gets USD 12 JPMorgan target before FDA date

October 8, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.

October 8, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

October 7, 2026 | marketbeat.com

JPMorgan Initiates Savara at Overweight With $12 Price Target

October 7, 2026 | marketscreener.comM

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

October 7, 2026 | streetinsider.com

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

October 7, 2026 | marketbeat.com

Savara stock fell 4.66 percent ahead of the November FDA decision

October 4, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Stock Bumped Down to "Sell" by Wall Street Zen

October 4, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

October 4, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Bank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRA

September 30, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen

September 26, 2026 | marketbeat.com

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?

September 24, 2026 | rttnews.com

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX, SVRA, KURA, and MLTX Company Descriptions

Kura Oncology NASDAQ:KURA

$9.61 -0.22 (-2.24%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$9.59 -0.02 (-0.24%)

As of 07:04 AM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.14 -0.27 (-2.59%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$10.02 -0.12 (-1.17%)

As of 07:02 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Neoleukin Therapeutics NASDAQ:NLTX

$21.56 -2.88 (-11.78%)

As of 10/13/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Savara NASDAQ:SVRA

$4.76 -0.02 (-0.42%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$5.00 +0.24 (+5.00%)

As of 06:33 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NLTX, SVRA, KURA, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NLTX, SVRA, KURA, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NLTX, SVRA, KURA, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX, SVRA, KURA, and MLTX Company Descriptions

Kura Oncology NASDAQ:KURA

MoonLake Immunotherapeutics NASDAQ:MLTX

Neoleukin Therapeutics NASDAQ:NLTX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NLTX, SVRA, KURA, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NLTX, SVRA, KURA, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NLTX, SVRA, KURA, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX, SVRA, KURA, and MLTX Company Descriptions

Kura Oncology NASDAQ:KURA

MoonLake Immunotherapeutics NASDAQ:MLTX

Neoleukin Therapeutics NASDAQ:NLTX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools